4.5 Article

Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.healun.2005.07.008

关键词

-

向作者/读者索取更多资源

Background: Right heart failure (RHF) is not an infrequent complication of left ventricular assist device (LVAD) i. mplantation. Few studies have examined outcomes for LVAD patients who subsequently develop RHF. Methods: One hundred eight patients with chronic CHF (>= 6 months) who underwent HeartMate LVAD implantation were identified during June 1996 to July 2004. Acute heart failure patients requiring LVADs were excluded to eliminate the impact of confounding non-cardiac factors. RHF was defined as the need for a subsequent right ventricular assist device (RVAD), :14 days of intravenous inotropes/pulmonary vasodilators, or both. Forty-two (38.9%) RI-IF patients were identified. Fourteen of these required RVAD insertion. Outcome parameters included early (<= 30-day) mortality, intensive care unit (ICU) length of stay (LOS), incidence of re-operation for bleeding and acute renal failure, and stroke, bridge-to-transplantation rate and post-transplantation survival rate. Results: More female patients developed RHF than not (73.3% vs 26.7%, p = 0.003). RHF patients had a higher early mortality rate, greater ICU LOS, higher rates of re-operation for bleeding and renal failure, and lower bridge-to-transplantation rate than non-RHF patients (19.0% vs 6.2%, p = 0.039; 23.8 +/- 23.7 vs 9.6 +/- 7.1 days, p < 0.001; 38.9% vs 18.3%, P = 0.026; 61.0% vs 22.6%, p < 0.001; 65.0% vs 89.9%, p = 0.003; respectively). Fourteen (33.3%) RHF patients required RVAD insertion. Elevated intra-operative central venous Pressure (CVP) was found to be an independent predictor of post-LVAD RHF. Overall bridge-to-transplantation rate for the entire study cohort was 73.1%. Conclusions: The development of RHF after LVAD insertion confers. significant morbidity and mortality. judicious application of inotropes and pulmonary vasodilators and timely RVAD insertion, if necessary, should be maintained. Further investigations evaluating pre- and intra-operative risk factors for the development of RHT are warranted. J Heart Lung Transplant 2006;25:1-6. Copyright (c) 2006 by the International Society for Heart and Lung Transplantation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据